<ul>
	<li>Melanoma: 200 mg every 3 weeks</li>
	<li>NSCLC: 200 mg every 3 weeks</li>
	<li>SCLC: 200 mg every 3 weeks</li>
	<li>HNSCC: 200 mg every 3 weeks</li>
	<li>cHL or PMBCL: 200 mg every 3 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics</li>
	<li>Urothelial Carcinoma: 200 mg every 3 weeks</li>
	<li>MSI-H Cancer: 200 mg every 3 weeks for adults and 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics</li>
	<li>Gastric Cancer: 200 mg every 3 weeks</li>
	<li>Esophageal Cancer: 200 mg every 3 weeks</li>
	<li>Cervical Cancer: 200 mg every 3 weeks</li>
	<li>HCC: 200 mg every 3 weeks</li>
	<li>MCC: 200 mg every 3 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics</li>
	<li>RCC: 200 mg every 3 weeks with axitinib 5 mg orally twice daily</li>
	<li>Endometrial Carcinoma: 200 mg every 3 weeks with lenvatinib 20 mg orally once daily for tumors that are not MSI-H or dMMR.</li>
</ul>

<p>Administer Pembrolizumab as an intravenous infusion over 30 minutes.</p>